Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2014

View Archived Issues

Lilly to initiate clinical study of cancer candidate LY-3164530

Asterias Biotherapeutics receives FDA clearance to begin phase I/IIa trial of AST-OPC1

Genentech acquires Seragon Pharmaceuticals and gains selective estrogen receptor degraders

Oprozomib receives FDA orphan drug designation for Waldenstrom's macroglobulinemia

FDA grants orphan drug designation to recombinant human pentraxin-2

Identification of a lncRNA biomarker for colorectal cancer prognosis

Generation of novel minimal saponin immunoadjuvant with improved profile

Robust non-human primate model of MERS-CoV

Host cell CDK9 prevents the replication of DNA viruses

Fujifilm begins phase I trial of FF-10501 in relapsed or refractory myelodysplastic syndromes

Isis begins phase III study of ISIS-APOCIII Rx in familial chylomicronemia syndrome

Discovery of novel antibacterial agents with improved in vivo clearance

Allergan divulges new S1P1 receptor agonists

Biotie regains global rights to tozadenant

Immunotech Laboratories completes early clinical testing of antiviral immunomodulator ITV-1

Scientists in China disclose novel xanthine oxidase inhibitors

Merck & Co. describes new NS5B inhibitors for HCV infection

FDA grants fast track status to Pfizer's Clostridium difficile vaccine

Amgen submits evolocumab BLA, reports Japanese phase III results

Cavion formed from merger of Tau Therapeutics and Xdynia

OncoPep completes financing round to support development of MM vaccine

Dezima reports findings from phase IIb study of TA-8995 for dyslipidemia

AstraZeneca's MEDI-4736 to be studied in immunological subsets of advanced colorectal cancer

Nuplazid selected as trade name for pimavanserin

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026